Tasbeeh Ahmed: Exploring Anticoagulation in Antiphospholipid Syndrome
Tasbeeh Ahmed, Medical Doctor, shared a post on LinkedIn:
“A clot may be the event. APS may be the reason.
Despite the widespread adoption of DOACs, Antiphospholipid Syndrome (APS) remains one of the most important exceptions in modern anticoagulation.
For many patients with thrombotic APS, the choice of anticoagulant is not just a prescription – it can determine the risk of recurrent DVT, stroke, limb ischemia, or pregnancy complications.
- When is Warfarin still the gold standard?
- Why are DOACs discouraged in triple-positive APS?
- What should we do when thrombosis recurs despite therapeutic INR?
- How does management change during pregnancy?
I created this infographic to provide a concise, evidence-based overview of the latest APS anticoagulation recommendations and help clinicians navigate these critical decisions with confidence.
Because in APS, choosing the right anticoagulant can be the difference between preventing the next thrombosis – or missing the opportunity.
What has been your experience managing APS patients in clinical practice?”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation